Eli Lilly Stock Falls Amid Discontinuation of Bimagrumab Trial in Obesity Patients with Type 2 Diabetes

Eli Lilly and Company (LLY) shares are trading lower after the company terminated a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes due to strategic business reasons. The drug was designed to preserve muscle while promoting fat loss, but safety concerns may have influenced the decision. Despite the setback, Lilly received positive news as the FDA approved Inluriyo for treating ESR1-mutated metastatic breast cancer.

Eli Lilly and Company (LLY) shares have been trading lower after the company terminated a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes. The decision, cited as strategic business reasons, comes just weeks after the study began.

The Phase 2b double-blind, randomized, placebo-controlled study aimed to evaluate the efficacy and safety of bimagrumab and tirzepatide, alone or in combination, in adult participants with obesity and Type 2 diabetes. The study was designed to enroll 180 overweight or obese patients over 13 months, with results originally expected by October 2026. The primary focus was weight loss, with a key secondary measure tracking fat versus muscle loss.

Bimagrumab, developed by Novartis AG (NVS) and later acquired by Lilly, is designed to preserve muscle while promoting fat loss by blocking a receptor that regulates muscle growth. However, safety concerns may have influenced the decision to terminate the study. A small diabetes trial conducted nearly a decade ago raised questions about safety, with one participant developing pancreatitis and requiring hospitalization. Other studies suggest diabetes patients may face a higher risk of pancreatic inflammation.

Despite the setback, Lilly received positive news as the FDA approved Inluriyo for treating ESR1-mutated metastatic breast cancer. The oral estrogen receptor antagonist reduced the risk of progression or death by 38% in a Phase 3 trial.

Eli Lilly shares were down 3.71% at $714.34 at last check on Thursday, according to Benzinga Pro Eli Lilly Stock Is Trading Down Thursday: What's Behind The Move?^[3].